Related Experiment Videos
Is a 9-month treatment sufficient in tuberculous enterocolitis? A prospective, randomized, single-centre study
1Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine and Clinical Research Institute, Seoul National University Hospital, Seoul, South Korea.
Alimentary Pharmacology & Therapeutics
|July 10, 2003
Summary
Nine-month anti-tuberculous therapy is effective for tuberculous enterocolitis, showing no recurrence. Further study is needed for immunocompromised patients with intestinal tuberculosis.
Area of Science:
- Gastroenterology
- Infectious Diseases
- Public Health
Background:
- Rising incidence of extra-pulmonary tuberculosis, particularly intestinal involvement, linked to HIV/AIDS and immunosuppression.
- Optimal treatment duration for intestinal tuberculosis remains unclear.
Purpose of the Study:
- To compare the efficacy of 9-month versus 15-month anti-tuberculous therapy for tuberculous enterocolitis.
- To evaluate response and recurrence rates based on treatment duration.
Main Methods:
- Prospective randomized trial of 40 patients with tuberculous enterocolitis.
- Diagnosis via colonoscopy, histopathology, or therapeutic trial.
- Follow-up with colonoscopy and clinical assessment.
Main Results:
- Complete response achieved in all patients regardless of treatment duration.
- Minor complications (intestinal obstruction, perianal fistula) occurred in a small number of patients.
- No recurrence of active intestinal tuberculosis observed during follow-up.
Conclusions:
- Nine-month chemotherapy is sufficient for managing tuberculous enterocolitis without recurrence.
- Further research is recommended for immunocompromised individuals.